tradingkey.logo
tradingkey.logo
Search

NeuroOne Medical Technologies Corp

NMTC
Add to Watchlist
4.210USD
-0.390-8.48%
Close 05/15, 16:00ETQuotes delayed by 15 min
36.29MMarket Cap
LossP/E TTM

NeuroOne Medical Technologies Corp

4.210
-0.390-8.48%

More Details of NeuroOne Medical Technologies Corp Company

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

NeuroOne Medical Technologies Corp Info

Ticker SymbolNMTC
Company nameNeuroOne Medical Technologies Corp
IPO dateNov 09, 2012
CEORosa (David A)
Number of employees17
Security typeOrdinary Share
Fiscal year-endNov 09
Address7599 Anagram Dr
CityEDEN PRAIRIE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55344-7399
Phone19524261383
Websitehttps://nmtc1.com/
Ticker SymbolNMTC
IPO dateNov 09, 2012
CEORosa (David A)

Company Executives of NeuroOne Medical Technologies Corp

Name
Name/Position
Position
Shareholding
Change
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
123.37K
-0.33%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
40.60K
+17.21%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
33.11K
-15.23%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
24.17K
+28.92%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
22.32K
+31.31%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
15.43K
-0.98%
Mr. Ronald (Ron) Mcclurg
Mr. Ronald (Ron) Mcclurg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher R. Volker
Mr. Christopher R. Volker
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Emily Johns
Ms. Emily Johns
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Mr. Chris Donovan
Mr. Chris Donovan
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
123.37K
-0.33%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
40.60K
+17.21%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
33.11K
-15.23%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
24.17K
+28.92%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
22.32K
+31.31%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
15.43K
-0.98%

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merchant Adventure Fund LP
8.12%
Bleichroeder LP
7.73%
Bard Associates Inc.
3.56%
Perkins Capital Management, Inc.
2.85%
Vanguard Capital Management, LLC
2.70%
Other
75.04%
Shareholders
Shareholders
Proportion
Merchant Adventure Fund LP
8.12%
Bleichroeder LP
7.73%
Bard Associates Inc.
3.56%
Perkins Capital Management, Inc.
2.85%
Vanguard Capital Management, LLC
2.70%
Other
75.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.60%
Corporation
8.31%
Individual Investor
5.89%
Hedge Fund
3.86%
Investment Advisor/Hedge Fund
2.13%
Research Firm
0.18%
Venture Capital
0.17%
Bank and Trust
0.04%
Other
60.82%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
58
2.36M
28.07%
-230.40K
2025Q4
52
16.89M
33.49%
-598.07K
2025Q3
51
17.15M
34.30%
+9.56M
2025Q2
52
13.28M
26.66%
+2.81M
2025Q1
54
11.51M
24.26%
+968.46K
2024Q4
55
12.46M
40.67%
+1.38M
2024Q3
55
11.22M
39.84%
+2.23M
2024Q2
51
10.72M
41.07%
+2.35M
2024Q1
52
11.45M
45.01%
+2.75M
2023Q4
57
9.37M
38.68%
+871.77K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Merchant Adventure Fund LP
4.20M
8.29%
--
--
Dec 31, 2025
Bleichroeder LP
4.00M
7.89%
--
--
Dec 31, 2025
Bard Associates Inc.
1.85M
3.64%
-4.00K
-0.22%
Dec 31, 2025
Perkins Capital Management, Inc.
1.47M
2.91%
+5.00K
+0.34%
Dec 31, 2025
Sio Capital Management, LLC
1.14M
2.25%
-1.22M
-51.71%
Dec 31, 2025
Renaissance Technologies LLC
763.03K
1.51%
+70.43K
+10.17%
Dec 31, 2025
Rosa (David A)
745.12K
1.47%
-71.33K
-8.74%
Feb 18, 2026
Geode Capital Management, L.L.C.
504.51K
1%
+7.68K
+1.54%
Dec 31, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Apr 14, 2026
Merger
6→1
Date
Ex-dividend Date
Type
Ratio
Apr 14, 2026
Merger
6→1
KeyAI